Nuveen LLC Makes New Investment in Organogenesis $ORGO

Nuveen LLC acquired a new stake in Organogenesis (NASDAQ:ORGO - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 171,776 shares of the company's stock, valued at approximately $742,000. Nuveen LLC owned about 0.14% of Organogenesis at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Merit Financial Group LLC acquired a new stake in shares of Organogenesis during the 1st quarter worth about $45,000. Victory Capital Management Inc. acquired a new stake in shares of Organogenesis during the 1st quarter worth about $67,000. ProShare Advisors LLC boosted its stake in shares of Organogenesis by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock worth $65,000 after purchasing an additional 6,689 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Organogenesis during the 4th quarter worth about $69,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Organogenesis during the 4th quarter worth about $111,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ORGO shares. BTIG Research reaffirmed a "buy" rating on shares of Organogenesis in a research note on Tuesday, July 15th. Cantor Fitzgerald raised their price target on shares of Organogenesis from $7.00 to $9.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Organogenesis presently has an average rating of "Moderate Buy" and a consensus target price of $7.50.

Organogenesis Stock Down 0.6%

Shares of ORGO stock traded down $0.03 during trading hours on Friday, hitting $5.00. 402,012 shares of the company were exchanged, compared to its average volume of 722,645. The firm has a market cap of $634.30 million, a PE ratio of -35.71 and a beta of 1.75. Organogenesis has a 1 year low of $2.45 and a 1 year high of $6.71. The firm has a fifty day moving average of $4.62 and a 200 day moving average of $4.23.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. The business had revenue of $101.01 million during the quarter, compared to analysts' expectations of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.